Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study

ABSTRACT: Take Home Message This retrospective study found some evidence of potential lower response rates and shortened overall survival following anti–programmed death-(ligand) 1 therapy in patients with metastatic urothelial carcinoma with prespecified fibroblast growth factor receptor alterations (FGFRa) than in those without FGFRa who received prior immunotherapy between May 2018 and July 2019.

Background

Clinical outcomes of anti–programmed death‑(ligand) 1 (anti–PD-[L]1) therapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa+) remain unclear; recent studies have reported either comparable or poorer outcomes versus patients without FGFR alterations (FGFRa–).

Objective

To analyze the outcomes

SUBMITTER: Rezazadeh Kalebasty A 

PROVIDER: S-EPMC9806713 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature